Angiogenesis 2021: Imaging among the focal points for February 12 agenda

Article

Three sessions cover the range from clinical updates for imaging to emerging therapies for non-exudative AMD.

Angiogenesis 2021: Imaging among focal points of Feb 12 agenda

The Bascom Palmer Eye Institute continues its annual Angiogenesis, Exudation, and Degeneration 2021 meeting this February in a virtual setting across 2 days from Friday, Feb. 12, through Saturday, Feb. 13.

Here is an overview of the planned offerings for Friday, which includes 3 sessions.

Following opening remarks by the program co-directors—Philip J. Rosenfeld, MD, PhD; Harry W. Flynn Jr., MD; and Thomas A. Albini, MD—the presentations will commence at 8 am Eastern.

Session I: Imaging Normal and Non-Exudative AMD Eyes includes the following:

  • Histopathology of Basal Laminar Deposits and Bruch’s Membrane in AMD
    Christine A. Curcio, PhD
  • Ultra-High Resolution SD-OCT in Normal Aging and AMD, James G. Fujimoto, PhD
  • Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT, Ruikang (Ricky) Wang, PhD
  • Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth, Eric M. Moult, BSc
  • The Status of the Choriocapillaris in Nascent GA, Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS
  • Rate of Progression of iRORA to cRORA in AMD, David Sarraf, MD
  • En Face OCT Imaging Simplifies the Detection of Pre-cRORA Lesions
    Philip J. Rosenfeld, MD, PhD

Session II: Imaging Eyes With Exudative AMD will begin at 9:30 am Eastern and feature:

  • OCTA Biomarkers for CNV Secondary to AMD, Seung-Young Yu, MD
  • Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology, Usha Chakravarthy, MD
  • Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules, K. Bailey Freund, MD
  • Home OCT Based Management of Neovascular AMD, Anat Loewenstein, MD

Session III: Emerging Therapies for Non-Exudative AMD, beginning at 10:30 am Eastern, is the final session of the day and will include:

  • Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy, Nadia K. Waheed, MD, MPH
  • C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy, Pravin U. Dugel, MD
  • Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Study Results, Charles C. Wykoff, MD, PhD
  • C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD, Cedric G. Francois, MD, PhD
  • Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials?, Glenn J. Jaffe, MD
  • Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD, SriniVas R. Sadda, MD
  • Update on Elamipretide for the Treatment of AMD , Jeffrey S. Heier, MD

Attendees will reconvene at 8 am on Saturday, Feb. 13, for the second day of the program.

To attend the virtual meeting, registration must be received by Tuesday, February 9, at noon EST. Conference registration is $100 and the number of registrants is limited.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
Abby Markward and Hattie Hayes discuss the ASCRS Annual Meeting, the ASOA Annual Meeting, and the Retina Day event.
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2025 MJH Life Sciences

All rights reserved.